STELLAR-303 trial – Talk Bio

Actionable Insights Powered by AI

Exelixis’ Kinase Blocker Zanzalintinib Sets New Survival Standard in Third-Line Metastatic Colorectal Cancer, Paving Way for FDA Review

3 days ago talkbio0Tagged Colorectal Carcinoma, Exelixis, kinase inhibitor [EPC], Overall Survival, regorafenib, STELLAR-303 trial, Submission, Tecentriq, Third line treatment, United States Food and Drug Administration, zanzalintinib

Exelixis; zanzalintinib; kinase inhibitor; colorectal cancer; STELLAR-303 trial; Tecentriq; regorafenib; overall survival; third-line therapy; FDA submission